These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 16932077)

  • 41. Heparin after angioplasty: an unresolved issue?
    More RS; Brack MJ; Gershlick AH
    Eur Heart J; 1993 Nov; 14(11):1543-7. PubMed ID: 8299638
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Recollection of the first heparin era].
    JORPES E
    Chemotherapia (Basel); 1961; 3():321-7. PubMed ID: 14452492
    [No Abstract]   [Full Text] [Related]  

  • 43. Safety and efficacy of low-dose unfractionated heparin during percutaneous coronary revascularisation and the relationship between activated clotting time and haemorrhagic or ischaemic complications: our results.
    Capuano C; Sesana M; Leonzi O; Cuccia C
    J Cardiovasc Med (Hagerstown); 2006 Dec; 7(12):866-71. PubMed ID: 17122672
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors.
    Harjai KJ; Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Na Y; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Rutherford BD; Lansky AJ; Mehran R
    Am J Cardiol; 2007 Jan; 99(2):202-7. PubMed ID: 17223419
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Is heparin still necessary after primary angioplasty in the era of platelet glycoprotein IIb/IIIa receptor inhibitors? A review of the literature.
    Lettieri C; De Servi S; Buffoli F; Aroldi M; Baccaglioni N; Romano M; Tomasi L; Izzo A; Zanini R
    J Cardiovasc Med (Hagerstown); 2006 Sep; 7(9):653-9. PubMed ID: 16932077
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antithrombotic therapy in patients undergoing coronary angioplasty.
    Popma JJ; Weitz J; Bittl JA; Ohman EM; Kuntz RE; Lansky AJ; King SB
    Chest; 1998 Nov; 114(5 Suppl):728S-741S. PubMed ID: 9822074
    [No Abstract]   [Full Text] [Related]  

  • 50. Dosing and administration of ReoPro (c7E3 Fab).
    Tcheng JE
    J Invasive Cardiol; 1994; 6 Suppl A():29A-33A; discussion 51A-54A. PubMed ID: 10155091
    [No Abstract]   [Full Text] [Related]  

  • 51. Restenosis: is there a pharmacologic fix in the pipeline?
    Keiser JA; Uprichard AC
    Adv Pharmacol; 1997; 39():313-51. PubMed ID: 9160119
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Medical progress exemplified by improvements in the safety coronary angioplasty].
    Metzger JP
    Bull Acad Natl Med; 2012 Oct; 196(7):1361-7; discussion 1367-8. PubMed ID: 23815020
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention.
    Lefkovits J; Topol EJ
    Prog Cardiovasc Dis; 1997; 40(2):141-58. PubMed ID: 9327830
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.